Education
About Us
Working with TipRanks
Follow Us
BioAge Labs, Inc. (BIOA)
NASDAQ:BIOA
BIOA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.80 - $26.62
Previous CloseN/A
Volume146.35K
Average Volume (3M)163.25K
Market Cap
$136.95M
Enterprise Value$387.03M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.87
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.05
Shares Outstanding35,850,037
10 Day Avg. Volume192,765
30 Day Avg. Volume163,249
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.60
P/FCF Ratio0.00
Enterprise Value/Market Cap2.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.64
Forecast
1Y Price Target
$5.67Price Target Upside48.43% Upside
Rating ConsensusHold
Number of Analyst Covering4
---
Bulls Say, Bears Say
Bulls Say
CollaborationsBioAge is involved in multiple discovery collaborations with major companies like Novartis and Lilly, aiming to identify and validate novel targets of aging and exercise.
Financial StabilityThe company's cash reserves of $334.5M provide financial stability and support planned clinical developments beyond 2029.
Pipeline ProgressBGE-102 continues to advance towards Phase 1 SAD data, indicating progress in the company's pipeline.
Bears Say
Program DiscontinuationThe discontinuation of the lead azelaprag program due to the emergence of liver transaminitis is a notable update.
Program SetbackThe recent pipeline setback resulted in the discontinuation of the lead program azelaprag.
Stock PerformanceBioAge shares are anticipated to remain somewhat range-bound given limited stock-moving catalysts.
---
Ownership Overview
13.57% Insiders
3.76% Mutual Funds
47.16% Other Institutional Investors
31.94% Public Companies and
Individual Investors
BIOA FAQ
What was BioAge Labs, Inc.’s price range in the past 12 months?
BioAge Labs, Inc. lowest stock price was $3.80 and its highest was $26.62 in the past 12 months.
What is BioAge Labs, Inc.’s market cap?
BioAge Labs, Inc.’s market cap is $136.95M.
When is BioAge Labs, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were BioAge Labs, Inc.’s earnings last quarter?
BioAge Labs, Inc. released its earnings results on Nov 07, 2024. The company reported -$6.7 earnings per share for the quarter, missing the consensus estimate of -$0.677 by -$6.023.
Is BioAge Labs, Inc. overvalued?
According to Wall Street analysts BioAge Labs, Inc.’s price is currently Undervalued.
Does BioAge Labs, Inc. pay dividends?
BioAge Labs, Inc. does not currently pay dividends.
What is BioAge Labs, Inc.’s EPS estimate?
BioAge Labs, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioAge Labs, Inc. have?
BioAge Labs, Inc. has 35,850,037 shares outstanding.
What happened to BioAge Labs, Inc.’s price movement after its last earnings report?
BioAge Labs, Inc. reported an EPS of -$6.7 in its last earnings report, missing expectations of -$0.677. Following the earnings report the stock price went up 7.614%.
Which hedge fund is a major shareholder of BioAge Labs, Inc.?
Currently, no hedge funds are holding shares in BIOA
---
BioAge Labs, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.67 (48.43% Upside)
$5.67 (48.43% Upside)
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $47.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 8.2%
Last 30 Days ▼ 8.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Company Description
BioAge Labs, Inc.
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
---
BIOA Stock 12 Month Forecast
Average Price Target
$5.67
▲(48.43% Upside)
Technical Analysis
Alnylam Pharma
―
BioMarin Pharmaceutical
―
Regeneron
―
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
Best Analysts Covering BIOA
1 Year
1 Year Success Rate
1/1 ratings generated profit
1 Year Average Return
+14.90%
reiterated a sell rating 11 days ago
Copying Michael Ulz's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +14.90% per trade.
---